No Data
No Data
Huafu Securities: The wave of state-owned enterprise reforms continues to deepen and the potential for state-owned pharmaceutical companies as symbols is enormous.
In the context of deepening state-owned enterprise reform and the new 'Nine Rules for the State', top central enterprises are expected to realize the catalysis of bullish resource integration, operational improvement, personnel optimization, and increased dividends.
China Traditional Chinese Medicine (00570.HK) was reduced by 1.514,000 shares by UBS Group AG
Gelonghui, May 24 | According to the latest equity disclosure data on the Stock Exchange, on May 20, 2024, China Traditional Chinese Medicine (00570.HK) was reduced by 15.014 million shares by UBS Group AG at an average price of HK$4.2,816 per share on the market, involving an investment of about HK$64,284 million. After reducing its holdings, UBS Group AG's latest number of positions was 298,902,715 shares, and the holding ratio dropped from 6.23% to 5.94%.
China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status
China Traditional Chinese Medicine Holdings (HKG:0570) and Sinopharm Common Wealth jointly announced that Sinopharm's representatives have been preparing required documents, notifications, filings and
中國中藥:2023年年報
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
China Traditional Chinese Medicine Posts 94% Profit Growth in 2023
China Traditional Chinese Medicine Holdings Co (HKG:0570) recorded a 93.6% rise in its net profit to 1.40 billion yuan in 2023, against 720.96 million yuan a year ago, according to a Thursday filing w
No Data